Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 3/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6069697 | 0.78 | LMNA (0.40) | L3MBTL1KDM4EMAPK1NPSR1MAPK14 | |
| SCHEMBL6070023 | 0.77 | TGFBR1 (0.32) | MAPK14MAPK10JAK2TGFBR1ROCK2 | |
| SCHEMBL6070097 | 0.74 | TGFBR1 (0.60) | L3MBTL1KDM4EMAPK1NPSR1MAPK14 | |
| SCHEMBL6132086 | 0.72 | TGFBR1 (0.50) | L3MBTL1KDM4EMAPK1NPSR1MAPK14 | |
| SCHEMBL6071083 | 0.71 | CDK2 (0.51) | CDK2 | |
| SCHEMBL29629023 | 0.71 | CYP4F2 (0.37) | NPSR1MAPK14CSNK1DJAK3CDK2 | |
| SCHEMBL2965363 | 0.70 | LMNA (0.47) | L3MBTL1KDM4EMAPK1NPSR1MAPK14 | |
| SCHEMBL2963770 | 0.70 | LMNA (0.47) | L3MBTL1KDM4EMAPK1MAPK14LMNA | |
| SCHEMBL6070786 | 0.68 | LMNA (0.44) | L3MBTL1KDM4EMAPK1NPSR1MAPK14 | |
| SCHEMBL16877199 | 0.68 | LMNA (0.42) | L3MBTL1KDM4EMAPK1NPSR1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109204-B2 | controlling signal transduction; anticancer agents, antitumor agents, atherosclerosis, vision defects, antidiabetic agents, antiinflammatory agents | MERCK & CO., INC. (US) | 2006-09-19 | — | — | US | disclosed |
| US-20040235875-A1 | drugs used for signal transduction modulation, and for prophylaxis of angiogenesis, cancers, tumors, atherosclerosis, vision disorders and inflammatory diseases in mammals | MERCK SHARP & DOHME CORP. | 2004-11-25 | — | — | US | disclosed |
| WO-2003011837-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235875-A1 | drugs used for signal transduction modulation, and for prophylaxis of angiogenesis, cancers, tumors, atherosclerosis, vision disorders and inflammatory diseases in mammals | FLT4, KDR, FLT1 | L3MBTL1 3645/4885KDM4E 4112/4885MAPK1 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.